PDCD1 and esophageal cancer: Phase I/II studies in pilot trials have demonstrated antitumor activity and safety of PD‐1/L1 based immunotherapy in patients with unresectable advanced or recurrent esophageal cancer or gastroesophageal junction cancer.9, 10, 11, 12, 13, 14, 15